- Home
- TENB vs RNA Comparison
TENB vs RNA Comparison
Compare TENB & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENB
- RNA
- Stock Information
- Founded
- TENB 2002
- RNA 2012
- Country
- TENB United States
- RNA United States
- Employees
- TENB N/A
- RNA N/A
- Industry
- TENB Computer Software: Prepackaged Software
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- TENB Technology
- RNA Health Care
- Exchange
- TENB Nasdaq
- RNA Nasdaq
- Market Cap
- TENB 4.8B
- RNA 5.5B
- IPO Year
- TENB 2018
- RNA 2020
- Fundamental
- Price
- TENB $41.68
- RNA $42.93
- Analyst Decision
- TENB Buy
- RNA Strong Buy
- Analyst Count
- TENB 16
- RNA 9
- Target Price
- TENB $50.60
- RNA $63.22
- AVG Volume (30 Days)
- TENB 1.2M
- RNA 1.1M
- Earning Date
- TENB 10-30-2024
- RNA 11-07-2024
- Dividend Yield
- TENB N/A
- RNA N/A
- EPS Growth
- TENB N/A
- RNA N/A
- EPS
- TENB N/A
- RNA N/A
- Revenue
- TENB $877,596,000.00
- RNA $10,117,000.00
- Revenue This Year
- TENB $14.43
- RNA $19.33
- Revenue Next Year
- TENB $9.64
- RNA $10.35
- P/E Ratio
- TENB N/A
- RNA N/A
- Revenue Growth
- TENB 13.97
- RNA N/A
- 52 Week Low
- TENB $35.25
- RNA $5.93
- 52 Week High
- TENB $53.50
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- TENB 51.16
- RNA 45.62
- Support Level
- TENB $40.21
- RNA $39.50
- Resistance Level
- TENB $43.26
- RNA $56.00
- Average True Range (ATR)
- TENB 0.95
- RNA 3.62
- MACD
- TENB -0.02
- RNA -0.44
- Stochastic Oscillator
- TENB 59.38
- RNA 23.94
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.